Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Basaglar in Indian Patients with Type 2 Diabetes (ABEX)
NCT04153981Phase 4Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2019
- Primary completion
- Jul 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of insulin glargine in type 2 diabetes mellitus (T2DM), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants With Hypoglycemic Events at 24 weeks. Started Dec 2019; status: completed.
02
Drugs
insulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04153981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04153981.